Skip to content
Oncology Research Hub

Grand Rapids, Michigan

Cancer clinical trials in Grand Rapids, MI

155 cancer studies are recruiting participants at sites in Grand Rapids as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Grand Rapids at a glance

  • 155 studies are recruiting at a site in Grand Rapids.
  • By phase: Early Phase 1 (1), Phase 1 (45), Phase 1/2 (26), Phase 2 (17), Phase 2/3 (5), Phase 3 (50), No phase (3), Observational (8). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (105), university, hospital or other (36), government (14).
  • By research area: Breast Cancer (50), Lung Cancer (38), Lymphoma (30), Prostate Cancer (18), Melanoma (10), Pancreatic Cancer (9).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Grand Rapids

Basic details from each study's public record (the 30 most recently updated of 155). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Cancer and Hematology Centers of Western Michigan
    Registry record
    NCT05696626 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START Midwest
    Registry record
    NCT07488676 · updated
  3. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Spectrum Health at Butterworth Campus
    Registry record
    NCT03418961 · updated
  4. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05564377 · updated
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06058377 · updated
  6. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    South Texas Accelerated Research Therapeutics (START)
    Registry record
    NCT06270706 · updated
  7. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    START Midwest - Oncology
    Registry record
    NCT06638307 · updated
  8. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    START Midwest
    Registry record
    NCT04557449 · updated
  9. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    START Midwest, LLC
    Registry record
    NCT06827236 · updated
  10. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cancer & Hematology Centers of Western Michigan ( Site 0026)
    Registry record
    NCT06841354 · updated
  11. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Helen DeVos Children's Hospital at Spectrum Health · Spectrum Health at Butterworth Campus · Trinity Health Grand Rapids Hospital
    Registry record
    NCT03723928 · updated
  12. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Immunomic Therapeutics, Inc.
    Study site
    START Midwest
    Registry record
    NCT07652242 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Grand Rapids

  1. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    START Midwest, LLC
    Registry record
    NCT07903415 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06096844 · updated
  4. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06498635 · updated
  5. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Corewell Health · Corewell Health - Butterworth Hospital · Corewell Health - Lemmen Holton Cancer Pavilion
    Registry record
    NCT06758401 · updated
  6. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    START | Midwest
    Registry record
    NCT06914128 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Grand Rapids

  1. First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07332455 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Grand Rapids

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT07068074 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Grand Rapids

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Corewell Health
    Registry record
    NCT06806033 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Corewell Health ( Site 0130)
    Registry record
    NCT06717347 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT05675410 · updated
  6. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
    Registry record
    NCT06337318 · updated
  7. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Corewell Health the Michigan Cancer Consortium
    Registry record
    NCT06846671 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Grand Rapids

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US078
    Registry record
    NCT07522073 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    START Midwest
    Registry record
    NCT07644559 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.

Ask about studies near Grand Rapids

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call